Engineered Beta-Like Cells for Type 1 Diabetes

Engineered Beta-Like Cells for

Type 1 Diabetes

The Challenge

The Crisis of Type 1 Diabetes

Type 1 Diabetes is a chronic autoimmune condition where the body’s own immune system destroys the insulin-producing beta cells in the pancreas. Without insulin, the body cannot effectively move glucose from the bloodstream into cells for energy. This condition affects an estimated 2 million Americans, including 304,000 children and adolescents. Patients face a lifetime of dependence on insulin injections and are at risk for severe complications, such as:

Chronic Kidney Disease, potentially leading to kidney failure
Eye problems including retinopathy, cataracts, and glaucoma
Heart disease and stroke
Peripheral and autonomic nerve damage (neuropathy)

The total estimated cost of Type 1 Diabetes in the United States is $813 billion.

The Mesogen Solution: Personalized Cell Therapy

Mesogen is solving this crisis with a revolutionary approach: providing autologous engineered Insulin-Producing Beta-Like Cells for transplant. We use a patient’s own cells to grow a new supply of Beta-Like cells through a proprietary process that takes approximately 6 weeks.

Because this therapy is autologous (derived from the patient), it does not require the use of long-term, burdensome anti-rejection drugs. Our goal is to provide a definitive treatment that allows patients to live with a better quality of life and fewer complications.

How Our Technology Works

Our innovative process engineers a patient’s own stem cells into a functional, insulin-producing cell graft transplant.

Bone Marrow Aspiration: The process starts with obtaining a sample of the patient's own bone marrow.
Stem Cell Isolation & Expansion: We isolate mesenchymal stem cells (MSCs) from the marrow and expand them to create a robust cell population.
Differentiation to Beta-Like Cells: The MSCs are guided through a proprietary, 4-stage differentiation process, transforming them into clusters of beta-like, insulin-producing cells.
Subcutaneous Placement: The functional insulin producing cell graft product is transplanted back to the patient through a simple subcutaneous injection.
Integration and Function: Following transplantation, blood capillaries grow around the new cells, integrating them into the body and allowing them to secrete insulin into the bloodstream.

Key Advantages & Scientific Validation

Our technology is differentiated by its unique advantages, which are backed by extensive validation data.

Autologous and Immune-Compatible: Our therapy uses the patient's own cells to create a functional insulin producing Beta-Like cell graft, which is a significant advantage. Crucially, our validation studies show that the auto-antibodies responsible for Type 1 Diabetes do not attack our engineered Beta-Like Cells. This eliminates the need for lifelong immunosuppression required by other transplant methods.
Proven Insulin and C-Peptide Response: Laboratory studies confirm the functionality of our cells. They secrete insulin in proportional response to increasing glucose levels. Furthermore, they produce C-peptide, a confirmatory marker that proves the cells are creating and releasing active insulin themselves.
Long-Term Functionality: Our Beta-Like cells have demonstrated the ability to consistently secrete high levels of insulin over extended periods in culture, showing an enhanced output over time.
Minimally Invasive Delivery: Unlike therapies that require a surgical transplant of cells, our treatment is delivered via a subcutaneous injection.

How it Works

A Cure Is Coming

Take The First Step Towards Your Future

Take control of your future and get in touch with us today to explore how Mesogen can assist you. Whether you’re a physician or a patient, we’re actively engaged in different stages of development and would love to discuss how we can support your goals. Don’t hesitate, reach out today!